The tissue expression of MCT3, MCT8, and MCT9 genes in women with breast cancer

Abstract

Background: Breast cancer (BC) is a common malignancy with a high mortality rate. Malignant cell transformation is associated with metabolic changes. One group pf proteins that are affected are the monocarboxylate transporters (MCTs-SLC16A). The MCTs comprise 14 members, and they play an important role in the growth, proliferation, and metabolism of cancer cells by transporting monocarboxylates such as lactate, pyruvate and thyroid hormones. We aimed to evaluate the expression of MCT3 (SLC16A8), MCT8 (SLC16A2) and MCT9 (SLC16A9) genes in breast cancer samples, comparing to normal adjacent tissues.Methods: Forty paired breast cancer tumor samples, the adjacent non-tumor and ve healthy tissues were collected. Three cancer cell lines (MCF-7, MDA-MB-231, and SKBR3) were also analysed. The expression of SLC16A8, SLC16A2 and SLC16A9 were assessed using quantitative real-time PCR (qRT-PCR). The relationship between gene expression with the pathological features of the tumors, and the hormone receptors status [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] of the patients tumors were also analyzed. Microarray data and survival analyses for each of the candidate genes was undertaken Results: There was a signi cantly lower expression of the MCT3 gene in tumor samples compared to adjacent normal tissue and healthy samples (P-value < 0.05). There was a signi cant difference in the expression of all three candidate genes between the BC tissues and normal tissues, and for the, tissues with different hormone receptor status (ER, PR and HER2) and the molecular subtypes. Altered MCT8 and MCT9 gene expression was associated with a reduced survival Conclusion: MCT3 expression is signi cantly downregulated in breast cancer tissue. MCT3 may represent a novel therapeutic target in breast cancer patients, or in some hormone receptor subgroups, such as HER2-negative or triple-negative.

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

“…Women worldwide are most likely to develop breast cancer with a high rate of mortality [ 67 , 68 ]. Despite improvements in chemotherapeutic agents, new strategies to overcome tumor cell survival remain elusive despite progress in understanding the mechanisms of chemoresistance [ 69 , 70 ].…”

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect

“…The recognition of tumor markers is necessary for the development of targeted therapy approaches [42,43]. Here, HCC tumor markers are presented, some of which are used in immunotoxin immunotherapy, and some of them could be good candidates in this regard (Table 1).…”

Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer

“…With the rapid development of sequencing technology, human awareness of disease has entered the genetic molecular level. Analysis of RNA sequencing (RNA-seq) data has revealed potential pathogenic genes and key molecules in various types of disease including cancer ( Park, 2021 ; Sohrabi et al, 2021 ). The vigorous development of high-throughput sequencing technology and bioinformatics has provided a powerful tool for revealing the underlying molecular mechanism of breast cancer.…”